Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
18 Dicembre 2023 - 10:53PM
Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”)
a biopharmaceutical company focused on modality-agnostic targeted
oncology therapies, today announced that Chief Executive Officer,
Nadim Ahmed, will present at the 42nd Annual J.P. Morgan Healthcare
Conference, being held January 8-11, 2024 in San Francisco, CA. Mr.
Ahmed’s presentation is scheduled for Thursday, January 11, at
10:30 am PST (1:30 pm EST).
A live webcast of the presentation will be available via the
Events and Presentations section of the Company’s investor
relations website at
https://cullinanoncology.com/events-and-presentations/.
About Cullinan Oncology
Cullinan Oncology, Inc. (Nasdaq: CGEM) is a biopharmaceutical
company dedicated to creating new standards of care for patients
with cancer. We innovate without borders to find the most promising
clinic-ready cancer therapies, whether from our own discovery
efforts or through exceptional engagement with our academic and
industry partners. Anchored in a deep understanding of
immuno-oncology and translational cancer medicine, we leverage our
scientific excellence in small molecules and biologics to create
differentiated ideas, identify unique targets, and select the
optimal modality to develop transformative therapeutics across
cancer indications. Powered by our novel research model, we push
conventional boundaries from candidate selection to cancer
therapeutic, applying rigorous early experimentation to fast-track
only the most promising assets to the clinic and ultimately
commercialization. As a result, our diversified pipeline is
strategically built with assets that activate the immune system or
inhibit key oncogenic drivers across a wide range of modalities,
each with the potential to be the best or first in their class.
Our people possess deep scientific expertise, seek innovation
openly, and exercise creativity and urgency to deliver on our
promise to bring new therapeutic solutions to patients with cancer.
Learn more about our Company at www.cullinanoncology.com, and
follow us on LinkedIn and Twitter.
Contacts:
InvestorsChad Messer+1
203.464.8900cmesser@cullinanoncology.com
MediaRose Weldon+1
215.801.7644rweldon@cullinanoncology.com
Grafico Azioni Cullinan Therapeutics (NASDAQ:CGEM)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Cullinan Therapeutics (NASDAQ:CGEM)
Storico
Da Lug 2023 a Lug 2024